Artificial Intelligence in Diagnostics Market Share

North America Market Analysis

The AI in diagnostics market in North America is projected to hold 41.5% of the revenue share during the forecast period owing to strong healthcare infrastructure with more technology-advanced adoptions. The increasing demand for precision diagnosis, mainly for chronic diseases such as cancer and cardiovascular conditions, drives the adoption of AI. AI-powered diagnostic tools result in better outcomes because the precision of the diagnosis allows for more personalized and targeted treatments. The robust investments in R&D in healthcare AI will further accelerate this artificial intelligence in diagnostics market growth and create opportunities for both large and small AI companies.

The adoption of AI in diagnostics in the U.S. is rising at a rapid pace due to the presence of established companies and advancements in technology. For example, in November 2022, Google partnered with iCAD to further commercialize mammography AI in support of its latest initiatives to advance the detection of breast cancer. This signals that more and more AI is being used in the early detection and diagnosis of critical diseases. The U.S. healthcare system places much emphasis on early diagnosis and preventive care, making it fertile ground for the implementation of AI technologies in diagnostics, hence positioning it to lead in the global artificial intelligence in diagnostics market.

Although Canada is witnessing relatively moderate growth than the U.S., the country is anticipated to present significant opportunities for the players in artificial intelligence in diagnostics market. In September 2023, the Mayo Clinic and GE HealthCare collaborated on the development of AI-powered diagnostic solutions—a demonstration of the country's focus on improving diagnostic accuracy and treatment outcomes. This deal is part of the broader strategy of Canada in enhancing the capability of its healthcare system through the use of AI to make diagnoses more efficient, reduce wait times, and improve patient outcomes for a wide range of conditions from cancer to cardiovascular diseases.

Asia Pacific Market Analysis

Asia Pacific artificial intelligence in diagnostics market is expected to record a CAGR of 22% during the forecast period due to rising healthcare needs and investments by governments of different countries in AI technology. The region hosts an increasing population, especially due to countries such as China and India, where the demand for effective healthcare solutions is increasing significantly. Therefore, various governments throughout the region are supporting or promoting the use of AI technologies to share the burden of healthcare, improve diagnosis, and provide more personalized care to patients. These factors, therefore, position Asia Pacific as one of the fastest-growing markets in AI diagnostics.

The AI in diagnostics companies in China are scaling new heights, in particular, on grounds of extensive government support for innovation in healthcare and the development of AI. In June 2024, the AI-powered patient management solution launched by Aidoc entered China, targeting better clinical workflows and patient care. This reflects China's aspiration to bring more AI into its healthcare to increase diagnostic precision and improve patient outcomes. The government is also actively supportive of AI initiatives for healthcare, driving the adoption across hospitals and diagnostic centers.

The demand for AI in diagnostics is anticipated to surge in India. A large population base, besides the increasing incidence rates of chronic diseases like diabetes and cancer, further contributes to an increased demand for more efficient diagnostic tools. The government's initiative to popularize AI in healthcare and increasing investments in healthcare infrastructure propels the artificial intelligence in diagnostics market growth. Although still in the pioneer stage of AI introduction, India has been trying to implement AI-based diagnostic instruments to improve diagnostic precision with less burden on human healthcare professionals.